How would you feel if one medicine meant to cure one disease cures another as well?
A new study by German and Dutch scientists has asserted that diabetic drug “Metformin” not only cures diabetes, but also reduces LDL cholesterol that is firmly believed to endorse cardiovascular diseases by triggering atherosclerosis.
The study was performed by researchers at Helmholtz Zentrum Munchen and German Diabetes Center Dusseldorf. The team looked into over 1,800 blood models of individuals who participated in a widespread study called “KORA”.
The research team inspected both the metabolites and genetics of these individuals and discovered that Metformin escorted to an alteration in metabolite levels.
Rui Wang-Sattler who is associated with the Helmholtz Zentrum Munchen conjectured that consumption of Metformin influences the LDL cholesterol levels via AMPK – a indicating path, directing “to a down-regulation of the genes FADS1 and 2.
She further explained that Metformin also reduces the levels of “three lipid metabolities” that depends of FADS. “Presumably, this is the mechanism how the production of LDL cholesterol is repressed by Metformin,” she added.
Tao Xu who is the first author of the study said that their research put forward the fact that Metformin “might indeed have an additional beneficial effects” related to cardiovascular problems in those individuals who suffer from diabetes.
Now the research team aims to see how Metformin operates on the molecular level. Stefan Brandmajer who is the co-first author of the study said that the correct mechanism behind Metformin reducing LDL cholesterol levels in still indistinct, therefore they looks to resume their study on “its decryption”.
Metformin, taken orally is the anti-diabetes drug that is most ancient and most usually employed to fight diabetes. Although, the mechanism is still ambiguous the drug has previously proved to impede gluconeogenesis in the liver.
The study has been published in the journal Diabetes Care.
This discovery comes off after our earlier report showed that diabetic drug could decrease the risk of getting Parkinson’s disease.
The research, which was performed by the London School of Hygiene & Tropical Medicine, discovered that individuals who suffered from diabetes and consumed glitazone antidiabetes drugs had a 28 percent decreased chance of getting Parkinson’s disease as compared to diabetic patients who followed other treatments, and never consumed glitazones.
This study was published in the journal PLOS Medicine.
According to the World Health Organization (WHO), report, in 2014 9 percent of the world population were believed to have a prevalence of diabetes with 1.5 million people dying of it in 2012.
It also predicted that diabetes will become the 7th foremost cause of death by 2030.